Dr. Bhasker Rai Mehta, MD

Dr. Mehta practices at South Arlington Dialysis Center in Arlington, Texas.

Dr. Mehta's NPI, 1790787612, was assigned on August 11, 2005. Dr. Mehta graduated from St. George's Hospital Medical School in 1975. Dr. Mehta holds Texas license F9815.

Dr. Mehta's primary practice is South Arlington Dialysis Center, at 3415 South Cooper Street Suite 118, Arlington, TX 76015 in Tarrant County. The practice phone is (817) 465-8585.

Dr. Mehta's primary practice is South Arlington Dialysis Center in Arlington, Texas. The medical group on file is Arlington Nephrology. Dmand AI also links Dr. Mehta to 1 more dialysis center and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mehta practices, 3 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Mehta's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Mehta is board certified in internal medicine by the American Board of Internal Medicine. Dr. Mehta is licensed in Texas.

Dmand AI lists acute kidney failure, chronic kidney disease, fluid and electrolyte imbalances and kidney cysts among the conditions Dr. Mehta treats.

CMS data shows 286 Medicare services from Dr. Mehta across 3 procedure codes in 2024, for 99 Medicare patients. Medicare paid $50,588 for them. Every service was in an office.

CMS counts 99 Medicare patients who saw Dr. Mehta in 2024. The largest group is 65 to 74, with 38 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. Their average risk score is 3.41, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mehta's median patient age at 72, with 44% women.

In 2024, Dr. Mehta wrote 1,968 Medicare Part D claims for 243 patients. 75% of them were for generic drugs. CMS names the drug for 1,675 of them, across 50 drugs with 11 or more claims each, at $443,316 in total drug cost. In 2023, CMS named 1,946 claims across 52 drugs.

Dr. Mehta accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Mehta to 3 clinical trials, 2 of them phase 3 studies. Conditions studied include Polycystic Kidney, Autosomal Dominant, Polycystic Kidney Diseases and Renal Insufficiency, Chronic. Otsuka Pharmaceutical Development & Commercialization, Inc. sponsors the most, 2. Open Payments lists research payments to Dr. Mehta that name 4 trials.

CMS Open Payments shows 313 general payments to Dr. Mehta from 36 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 60% of the total. AstraZeneca Pharmaceuticals LP paid the most, $4,086. It also lists 6 research payments totaling $28,124 from 2017 to 2025, naming 4 clinical trials.

Dmand AI lists 1 award for Dr. Mehta, most recently CMS Stage 1 EHR in 2013.

Dr. Mehta graduated from St. George's Hospital Medical School in 1975.

Dr. Mehta is in network with 21 carriers, including Elevance, Aetna and United Healthcare. HMO plans come from the most carriers, 12. Check the plan with the practice before a visit.